Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Previously Marketed

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Acetylcholinesterase

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1959

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Accommodative esotropia

2

Open-angle glaucoma

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Palliative

2

Primary

2

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Chemie Linz

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

2

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

2

DAILYMED

2

DRUG BANK

2

EPA CompTox

2

EVMPD

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

SENSORY ORGANS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

OPHTHALMOLOGICALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTIGLAUCOMA PREPARATIONS AND MIOTICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Parasympathomimetics

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

1

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 2 of 2 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

DEMECARIUM

ILP8XJ8R5K

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1959

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Acetylcholinesterase

Conditions:

Accommodative esotropia

Open-angle glaucoma

Demecarium (HUMORSOL®) is an indirect-acting parasympathomimetic agent, also known as a cholinesterase inhibitor and anticholinesterase. Cholinesterase inhibitors prolong the effect of acetylcholine, which is released at the neuroeffector junction of...

parasympathetic postganglion nerves, by inactivating the cholinesterases that break it down. Application of demecarium (HUMORSOL®) to the eye produces intense miosis and ciliary muscle contraction due to inhibition of cholinesterase, allowing acetylcholine to accumulate at sites of cholinergic transmission. These effects are accompanied by increased capillary permeability of the ciliary body and iris, increased permeability of the blood-aqueous barrier, and vasodilation. Myopia may be induced or, if present, may be augmented by the increased refractive power of the lens that results from the accommodative effect of the drug. Demecarium (HUMORSOL®) indirectly produces some of the muscarinic and nicotinic effects of acetylcholine as quantities of the latter accumulate.

DEMECARIUM BROMIDE

61D5V4OKTP

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1959

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Acetylcholinesterase

Conditions:

Accommodative esotropia

Open-angle glaucoma

Demecarium (HUMORSOL®) is an indirect-acting parasympathomimetic agent, also known as a cholinesterase inhibitor and anticholinesterase. Cholinesterase inhibitors prolong the effect of acetylcholine, which is released at the neuroeffector junction of...

parasympathetic postganglion nerves, by inactivating the cholinesterases that break it down. Application of demecarium (HUMORSOL®) to the eye produces intense miosis and ciliary muscle contraction due to inhibition of cholinesterase, allowing acetylcholine to accumulate at sites of cholinergic transmission. These effects are accompanied by increased capillary permeability of the ciliary body and iris, increased permeability of the blood-aqueous barrier, and vasodilation. Myopia may be induced or, if present, may be augmented by the increased refractive power of the lens that results from the accommodative effect of the drug. Demecarium (HUMORSOL®) indirectly produces some of the muscarinic and nicotinic effects of acetylcholine as quantities of the latter accumulate.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1